Kailera Therapeutics to Participate in November Investor Conferences TMCnet News [November 03, 2026] | / | Kailera Therapeutics to Participate in November Investor Conferences WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) - Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferences: * Stifel 2026 Healthcare Conference November 10-12, 2026, New York, NY Presentation: Tuesday, November 10, 2026, at 4:00 pm ET * Jefferies Global Healthcare Conference in London November 16-19, 2026, London, UK Fireside Chat: Monday, November 16, 2026, at 10:00 am GMT * 9th Annual Evercore Healthcare Conference November 30-December 2, 2026, Coral Gables, FL Fireside Chat: Wednesday, December 2, 2026, at 8:45 am ET The live webcasts will be available on the Events page of Kailera's investor website. A replay of the conference webcast will be archived on the company's website for 90 days. About Kailera Therapeutics Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is xpanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera's vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA. For more information, visit www.kailera.com and follow Fog Computing World on LinkedIn and X. Special Note Regarding Kailera Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the profile of product candidates, the potential of Kailera's portfolio, market opportunities for product candidates, the competitive landscape, and participation in upcoming events. Forward-looking statements can be identified by terms such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "suggest," "plan," "goal," "vision," "potential," "predict," "project," "should," "target," "will," "would," or similar expressions and the negatives of those terms. Kailera cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption "Risk Factors" in Kailera's filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release, and Kailera undertakes no obligation to update or revise any forward-looking statements. Kailera may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. Contact Information Maura Gavaghan Vice President, Investor Relations [email protected] Anna Robinson Vice President, Communications [email protected] [ Back To TMCnet.com's Homepage] |

Kailera reports flexible ribupatide injection sites and early weight-loss signals with KAI-4729 in Phase 1. Kailera reports Phase 1 data showing flexible ribupatide injection sites and early weight-loss signals with KAI-4729, including 16% mean weight loss. Kailera Therapeutics presented new clinical findings from its obesity pipeline at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, highlighting Phase 1 data for ribupatide injection and KAI-4729. The data add clinical evidence for two investigational therapies targeting metabolic disease through different incretin-based approaches. Ribupatide shows similar exposure across injection sites. The Phase 1 ribupatide study (NCT07044401) evaluated whether the site of subcutaneous administration affected drug exposure or safety. The randomized, single-dose, three-period crossover study enrolled 51 adults with overweight or obesity. Participants received a single 2 mg dose of ribupatide during each 29-day treatment period, with injections administered at the abdomen, upper arm or thigh according to a randomized sequence. Plasma ribupatide exposure following administration in the upper arm or thigh was similar to exposure following abdominal injection. These findings support the upper arm and thigh as potential alternative subcutaneous injection sites for ribupatide. Ribupatide was generally well tolerated across the three injection sites. Most treatment-emergent adverse events were mild and gastrointestinal in nature, and the study identified no new safety signals associated with injection location. The findings could provide greater flexibility for patients using once-weekly subcutaneous ribupatide if the results are confirmed in later-stage development. KAI-4729 shows early weight-loss and liver-fat signals. Hengrui Pharma, Kailera's development partner, also presented Phase 1 (NCT06762600) findings for KAI-4729 (HRS-4729), an investigational GLP-1/GIP/glucagon receptor triple agonist. The randomized, double-blind, placebo-controlled first-in-human study evaluated safety, tolerability, pharmacokinetics and pharmacodynamics in adults across single-ascending-dose and multiple-ascending-dose cohorts. In the multiple-dose portion, participants received once-weekly doses of 1 mg, 4 mg, 8 mg or 12 mg KAI-4729, with 4 mg ribupatide serving as an active control. At Week 12, participants receiving 12 mg KAI-4729 showed a 16.0% mean reduction in body weight from baseline. The same cohort showed a 67.3% mean reduction in liver fat content. The 4 mg ribupatide active-control group, which included 10 participants, showed a 16.7% mean reduction in body weight and a 38.4% mean reduction in liver fat content at Week 12. Because these findings come from a small Phase 1 cohort, the results represent an early clinical signal rather than established efficacy. Further studies with larger populations and longer follow-up will be needed to characterize the treatment's weight-loss potential and metabolic effects. KAI-4729 and ribupatide were generally well tolerated in the study, with most treatment-emergent adverse events described as mild to moderate and gastrointestinal in nature. Kailera advances multiple GLP-1 programs. The EASD presentations also included Phase 2 and Phase 3 clinical data from Hengrui's programs that are now being developed globally by Kailera. These included ribupatide in Chinese participants with obesity and polyendocrine metabolic ovarian syndrome, as well as oral HRS-7535, an investigational small-molecule GLP-1 receptor agonist, in adults with type 2 diabetes. Kailera plans to initiate a Phase 1 study of KAI-4729 outside China in 2026, with data expected in 2027. Ribupatide injection is currently being evaluated in the global KaiNETIC Phase 3 program for obesity. Hengrui has also submitted a New Drug Application to China's National Medical Products Administration for ribupatide injection for long-term weight management in adults. Under a May 2024 agreement, Hengrui granted Kailera exclusive global rights outside Greater China to develop, manufacture and commercialize its portfolio of GLP-1-based therapies, including ribupatide injection, ribupatide oral and KAI-4729. The latest EASD findings therefore provide additional clinical data across Kailera's developing obesity portfolio, with ribupatide generating evidence supporting flexibility in injection-site administration and KAI-4729 producing an early signal of weight and liver-fat reduction that will require confirmation in subsequent clinical development. Reference. Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting, Kailera Therapeutics, 01 October 2026 A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices, ClinicalTrials.gov ID NCT07044401 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects, ClinicalTrials.gov ID NCT06762600 About the Writer Mayuri Vaja (Linkedin) is a Pharm.D professional with a strong interest in clinical research, pharmacovigilance, and medical writing, supported by certifications in pharmacovigilance and academic projects exploring AI in healthcare and drug safety. With a growing focus on evidence-based healthcare and scientific communication, she is developing expertise in clinical research and translating healthcare evidence into clear, meaningful content. As a Pharmacally healthcare writer, Mayuri is committed to creating accurate, research-driven, and clinically relevant healthcare content while continuously strengthening her professional skills.

Kailera Therapeutics to participate in September investor conferences. WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) - Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participation in the following investor conferences: * Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Wednesday, September 23, 2026, 9:40 a.m. ET Fireside Chat with Jamie Coleman, Chief Commercial Officer * Stifel 2026 Virtual Cardiometabolic Forum Wednesday, September 30, 2026, 11:30 a.m. ET Fireside Chat with Ron Renaud, Chief Executive Officer, Doug Pagán, Chief Financial Officer, and Scott Wasserman, Chief Medical Officer The live webcasts will be available on the Events page of Kailera's investor website. A replay of the conference webcasts will be archived on the company's website for 90 days. About Kailera Therapeutics Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera's vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA. For more information, visit www.kailera.com and follow us on LinkedIn and X. Special Note Regarding Kailera Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the profile of product candidates, the potential of Kailera's portfolio, market opportunities for product candidates, the competitive landscape, and participation in upcoming events. Forward-looking statements can be identified by terms such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "suggest," "plan," "goal," "vision," "potential," "predict," "project," "should," "target," "will," "would," or similar expressions and the negatives of those terms. Kailera cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption "Risk Factors" in Kailera's filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release, and Kailera undertakes no obligation to update or revise any forward-looking statements. Kailera may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. Contact Information Maura Gavaghan Vice President, Investor Relations [email protected]